<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.28673.002</object-id><label>Table 1.</label><caption><title>Seroprevalence of antibodies to 38 <italic>P. vivax</italic> proteins in Papua New Guinean children aged 1&#8211;3 years.</title></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="5" valign="bottom"/><th colspan="5">No. of children (%)</th></tr><tr><th>Location</th><th>Protein</th><th>Geom mean*</th><th colspan="2">95% CI*</th><th>1% of adult levels</th><th>5% of adult levels</th><th>10% of adult levels</th><th>25% of adult levels</th><th>50% of adult levels</th></tr></thead><tbody><tr><td rowspan="2">GPI-anchored merozoite surface</td><td>MSP1 19</td><td>0.47</td><td>0.38</td><td>0.57</td><td>152 (67.9)</td><td>67 (29.9)</td><td>38 (17.0)</td><td>21 (9.4)</td><td>13 (5.8)</td></tr><tr><td>&#8195;P12</td><td>0.02</td><td>0.02</td><td>0.03</td><td>33 (14.7)</td><td>2 (0.9)</td><td>0</td><td>0</td><td>0</td></tr><tr><td rowspan="8">Peripheral surface</td><td>MSP3a full</td><td>1.17</td><td>1.05</td><td>1.31</td><td>222 (99.1)</td><td>121 (54.0)</td><td>51 (22.8)</td><td>12 (5.4)</td><td>3 (1.3)</td></tr><tr><td>&#8195;MSP3a block 1</td><td>0.79</td><td>0.72</td><td>0.86</td><td>222 (99.1)</td><td>82 (36.6)</td><td>18 (8.0)</td><td>3 (1.3)</td><td>0</td></tr><tr><td>&#8195;MSP3a block 2</td><td>0.54</td><td>0.48</td><td>0.60</td><td>202 (90.2)</td><td>48 (21.4)</td><td>13 (5.8)</td><td>4 (1.8)</td><td>1 (0.4)</td></tr><tr><td>&#8195;MSP3a N-term</td><td>0.11</td><td>0.10</td><td>0.13</td><td>222 (99.1)</td><td>139 (62.0)</td><td>64 (28.6)</td><td>11 (4.9)</td><td>4 (1.8)</td></tr><tr><td>&#8195;MSP3a C-term</td><td>0.11</td><td>0.10</td><td>0.13</td><td>62 (27.7)</td><td>4 (1.8)</td><td>1 (0.4)</td><td>0</td><td>0</td></tr><tr><td>&#8195;MSP9 N-term</td><td>0.09</td><td>0.08</td><td>0.11</td><td>62 (27.7)</td><td>7 (3.1)</td><td>3 (1.3)</td><td>0</td><td>0</td></tr><tr><td>&#8195;P41</td><td>0.02</td><td>0.02</td><td>0.02</td><td>20 (8.9)</td><td>8 (3.6)</td><td>3 (1.3)</td><td>0</td><td>0</td></tr><tr><td>&#8195;SERA</td><td>0.96</td><td>0.87</td><td>1.07</td><td>224 (99.6)</td><td>93 (41.4)</td><td>38 (16.9)</td><td>8 (3.6)</td><td>3 (1.3)</td></tr><tr><td rowspan="9">Microneme</td><td>AMA1</td><td>0.41</td><td>0.36</td><td>0.47</td><td>167 (74.6)</td><td>34 (15.2)</td><td>19 (8.5)</td><td>5 (2.2)</td><td>1 (0.4)</td></tr><tr><td>&#8195;DBPII Sal1</td><td>0.24</td><td>0.21</td><td>0.27</td><td>127 (56.7)</td><td>17 (7.6)</td><td>9 (4.0)</td><td>3 (1.3)</td><td>2 (0.9)</td></tr><tr><td>&#8195;DBPII P</td><td>0.23</td><td>0.19</td><td>0.28</td><td>125 (55.8)</td><td>26 (11.6)</td><td>12 (5.4)</td><td>3 (1.3)</td><td>3 (1.3)</td></tr><tr><td>&#8195;DBPII O</td><td>0.34</td><td>0.28</td><td>0.40</td><td>146 (65.2)</td><td>38 (17.0)</td><td>13 (5.8)</td><td>5 (2.2)</td><td>3 (1.3)</td></tr><tr><td>&#8195;DBPII AH</td><td>0.24</td><td>0.21</td><td>0.27</td><td>128 (57.1)</td><td>15 (6.7)</td><td>7 (3.1)</td><td>2 (0.9)</td><td>2 (0.9)</td></tr><tr><td>&#8195;DBPII C</td><td>0.23</td><td>0.19</td><td>0.27</td><td>125 (55.8)</td><td>26 (11.6)</td><td>11 (4.9)</td><td>3 (1.3)</td><td>3 (1.3)</td></tr><tr><td>&#8195;EBP</td><td>0.40</td><td>0.33</td><td>0.48</td><td>142 (63.1)</td><td>60 (26.7)</td><td>36 (16.0)</td><td>14 (6.2)</td><td>6 (2.7)</td></tr><tr><td>&#8195;GAMA</td><td>0.01</td><td>0.01</td><td>0.01</td><td>5 (2.2)</td><td>1 (0.4)</td><td>0</td><td>0</td><td>0</td></tr><tr><td>&#8195;CyRPA</td><td>0.54</td><td>0.42</td><td>0.69</td><td>139 (61.8)</td><td>78 (34.7)</td><td>54 (24.0)</td><td>40 (17.8)</td><td>31 (13.8)</td></tr><tr><td rowspan="8">Rhoptry</td><td>ARP</td><td>0.40</td><td>0.37</td><td>0.43</td><td>205 (91.1)</td><td>17 (7.6)</td><td>6 (2.7)</td><td>0</td><td>0</td></tr><tr><td>&#8195;RBP1a</td><td>0.41</td><td>0.35</td><td>0.47</td><td>162 (72.3)</td><td>39 (17.4)</td><td>18 (8.0)</td><td>9 (4.0)</td><td>3 (1.3)</td></tr><tr><td>&#8195;RBP2a</td><td>0.86</td><td>0.72</td><td>1.04</td><td>186 (83.0)</td><td>102 (45.5)</td><td>64 (28.6)</td><td>29 (12.9)</td><td>13 (5.8)</td></tr><tr><td>&#8195;RBP2b</td><td>1.19</td><td>1.02</td><td>1.38</td><td>209 (93.3)</td><td>130 (58.0)</td><td>90 (40.2)</td><td>12 (5.4)</td><td>3 (1.3)</td></tr><tr><td>&#8195;RBP2cNB</td><td>0.40</td><td>0.34</td><td>0.47</td><td>159 (71.0)</td><td>40 (17.9)</td><td>29 (12.9)</td><td>13 (5.8)</td><td>8 (3.6)</td></tr><tr><td>&#8195;RBP2-P2</td><td>1.68</td><td>1.49</td><td>1.91</td><td>224 (100.0)</td><td>156 (69.6)</td><td>89 (39.7)</td><td>24 (10.7)</td><td>13 (5.8)</td></tr><tr><td>&#8195;RhopH2</td><td>1.40</td><td>1.26</td><td>1.57</td><td>224 (99.6)</td><td>144 (64.0)</td><td>72 (32.0)</td><td>18 (8.0)</td><td>3 (1.3)</td></tr><tr><td>&#8195;RAMA</td><td>1.44</td><td>1.30</td><td>1.61</td><td>225 (100.0)</td><td>146 (64.9)</td><td>61 (27.1)</td><td>20 (8.9)</td><td>7 (3.1)</td></tr><tr><td rowspan="2">Pre-erythrocytic</td><td>CSP</td><td>0.15</td><td>0.12</td><td>0.18</td><td>95 (42.4)</td><td>21 (9.4)</td><td>8 (3.6)</td><td>2 (0.9)</td><td>1 (0.4)</td></tr><tr><td>&#8195;PVX_080665</td><td>0.68</td><td>0.61</td><td>0.76</td><td>214 (95.5)</td><td>59 (26.3)</td><td>28 (12.5)</td><td>4 (1.8)</td><td>1 (0.4)</td></tr><tr><td rowspan="9">Other</td><td>PVX_081550</td><td>0.03</td><td>0.03</td><td>0.04</td><td>6 (2.7)</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>&#8195;PVX_094350</td><td>1.44</td><td>1.30</td><td>1.59</td><td>225 (100.0)</td><td>148 (65.8)</td><td>65 (28.9)</td><td>15 (6.7)</td><td>6 (2.7)</td></tr><tr><td>&#8195;AKLP2</td><td>1.35</td><td>1.20</td><td>1.52</td><td>225 (100.0)</td><td>134 (59.6)</td><td>71 (31.6)</td><td>17 (7.6)</td><td>7 (3.1)</td></tr><tr><td>&#8195;PVX_087670</td><td>1.71</td><td>1.54</td><td>1.89</td><td>225 (100.0)</td><td>160 (71.1)</td><td>80 (35.6)</td><td>22 (9.8)</td><td>7 (3.1)</td></tr><tr><td>&#8195;PVX_122805</td><td>2.04</td><td>1.85</td><td>2.24</td><td>225 (100.0)</td><td>189 (84.0)</td><td>108 (48.0)</td><td>24 (10.7)</td><td>6 (2.7)</td></tr><tr><td>&#8195;CCp5</td><td>1.69</td><td>1.52</td><td>1.88</td><td>225 (100.0)</td><td>162 (72.0)</td><td>79 (35.1)</td><td>20 (8.9)</td><td>9 (4.0)</td></tr><tr><td>&#8195;PVX_114330</td><td>2.16</td><td>1.98</td><td>2.37</td><td>225 (100.0)</td><td>198 (88.0)</td><td>120 (53.3)</td><td>28 (12.4)</td><td>4 (1.8)</td></tr><tr><td>&#8195;Pv-fam-a/PVX_088820</td><td>2.38</td><td>2.17</td><td>2.60</td><td>225 (100.0)</td><td>209 (92.9)</td><td>127 (56.4)</td><td>32 (14.2)</td><td>6 (2.7)</td></tr><tr><td>&#8195;Pv-fam-a/PVX_092995</td><td>1.85</td><td>1.70</td><td>2.02</td><td>225 (100.0)</td><td>184 (81.8)</td><td>93 (41.3)</td><td>18 (8.0)</td><td>5 (2.2)</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: No&#160;=&#160;number; Geom mean&#160;=&#160;geometric mean; 95% CI&#160;=&#160;95% confidence interval. *IgG levels multiplied by 1000. Values are in relative antibody units interpolated from standard curves using a 5PL logistic regression model.</p></fn></table-wrap-foot></table-wrap>